Innate Pharma S.A. Reports Significant Updates in Form 6-K - December 20, 2024

Here's the key information extracted from the provided financial report section:

Document Overview

• Type: Form 6-K
• Date of Report: December 20, 2024
• Commission File Number: 001-39084

Company Information

• Company Name: Innate Pharma S.A.
• Address:
• 117 Avenue de Luminy—BP 30191
• 13009 Marseille, France
• Contact Number: +33 (0) 4 30 30 30

Filing Information

• Filing Type: Report of Foreign Private Issuer
• The registrant confirms that it files annual reports under Form 20-F.

Exhibit Information

• Exhibit 99.1: Press Release dated December 20, 2024.

Signatures

• The report is signed by:
• Name: Jonathan Dickinson
• Title: Chairman of the Executive Board and Chief Executive Officer
• Date of Signature: December 20, 2024

Insights

1. Nature of Filing: The report is a Form 6-K, which is typically used by foreign companies to report significant events or changes that may be of interest to investors.
2. Executive Leadership: The signature from Jonathan Dickinson indicates that he is actively engaged in the company’s reporting and governance.
3. Regulatory Compliance: By indicating the use of Form 20-F for annual reports, Innate Pharma demonstrates adherence to SEC regulations for foreign issuers, which can enhance investor confidence.

This information is crucial for understanding the company's compliance, governance, and operational updates as of the specified date.